A Microsimulation of the Cost-effectiveness of Maraviroc for Antiretroviral Treatment-Experienced HIV-Infected Individuals

REFERENCES

• Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpa-tient Study Investigators. N Engl J Med. 1998;338(13): 853–860.
   PubMed Web of Science ®Google Scholar
• Hellinger FJ. The lifetime cost of treating a person with HIV. J Am Med Assoc. 1993;270(4):474–478.
   PubMed Web of Science ®Google Scholar
• Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006;44(11):990–997.
   PubMed Web of Science ®Google Scholar
• Ewings FM, Bhaskaran K, McLean K, et al. Survival follow-ing HIV infection of a cohort followed up from seroconver-sion in the UK. AIDS. 2008;22(1):89–95.
   PubMed Web of Science ®Google Scholar
• Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001344(11):824–831.
   Web of Science ®Google Scholar
• Schackman BR, Freedberg KA, Weinstein MC, et al. Cost-effectiveness implications of the timing of antiret-roviral therapy in HIV-infected adults. Arch Intern Med. 2002;162(21):2478–2486.
   PubMed Web of Science ®Google Scholar
• Simpson KN, Luo MP, Chumney E, Sun E, Brun S, Ashraf T. Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection. HIV Clin Trials. 2004;5(5):294–304.
   PubMed Web of Science ®Google Scholar
• Weinstein MC, Goldie SJ, Losina E, et al. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med. 2001;134(6): 440–450.
   PubMed Web of Science ®Google Scholar
• Chan DC, Kim PS. HIV entry and its inhibition. Cell. 1998;93(5):681–684.
   PubMed Web of Science ®Google Scholar
• Wyatt R, Sodroski J. The HIV-1 envelope glycopro-teins: fusogens, antigens, and immunogens. Science. 1998;280(5371)1 884–1888.
   Web of Science ®Google Scholar
• Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for pre-viously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359(14)1 429–1441.
   Web of Science ®Google Scholar
• Hardy D, Reynes J, Konourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in treat-ment-experienced patients infected with CCR5-tropic HIV-1: 48-week combined analysis of the MOTIVATE studies. Presented at: 15th Conference on Retroviruses and Opportunistic Infections (CR01); 2008; Boston, MA. Abstract of poster presentation 792.
   Google Scholar
• Chancellor JV, Hill AM, Sabin CA, Simpson KN, Youle M. Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection. Pharmacoeconom-ics. 1997;12(1):54–66.
   PubMed Web of Science ®Google Scholar
• Hornberger J, Kilby JM, Wintfeld N, Green J. Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States. AIDS Res Hum Retro viruses. 2006;22(3):240–247.
   PubMed Web of Science ®Google Scholar
• Richter A, Hauber B, Simpson K, Mauskopf JA, Yin D. A Monte Carlo simulation for modelling outcomes of AIDS treatment regimens. Pharmacoeconomics. 200220(4): 215–224.
   Google Scholar
• Sax PE, Losina E, Weinstein MC, et al. Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease. J Acquir Immune Defic Syndr. 2005;39(1):69–77.
   PubMed Web of Science ®Google Scholar
• Schulman KA, Lynn LA, Glick HA, Eisenberg JM. Cost effectiveness of low-dose zidovudine therapy for asymp-tomatic patients with human immunodeficiency virus (HIV) infection. Ann Intern Med. 1991114(9):798–802.
   Google Scholar
• Multicenter AIDS Cohort Study (MACS) Public Data Set: Release PO4. Springfield, VA: National Technical Informa-tion Service; 1995.
   Google Scholar
• Cole SR, Hernan MA, Robins JM, et al. Effect of highly active antiretroviral therapy on time to acquired immuno-deficiency syndrome or death using marginal structural models. Am J EpidemioL 2003;158(7):687–694.
   PubMed Web of Science ®Google Scholar
• d'Arminio MA, Sabin CA, Phillips A, et al. The chang-ing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med. 2005;165(4): 416–423.
   PubMed Web of Science ®Google Scholar
• Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126(12):946–954.
   PubMed Web of Science ®Google Scholar
• Chancellor J, Kuehne FC, Weinstein M, Mollon P. Micro-simulation or cohort modeling? A comparative case study in HIV infection. Presented at: ISPOR 12th Annual Inter-national Meeting; 2007; Arlington, VA. Abstract of poster presentation PIN36, p. A170.
   Google Scholar
• Kilihne F, Chancellor J, Weinstein M, Mollon P. Microsimu-lation versus cohort modelling of antiretroviral therapy in treatment-naive and treatment-experienced populations. Presented at: Health Technology Assessment International (HTAi) IV Annual Meeting; 2007; Barcelona. Abstract of poster presentation M67.
   Google Scholar
• Kühne F, Chancellor J, Mollon P, Powderly WG. Microsim-ulation or cohort modelling? A comparative case study in HIV based on treatment experienced patients. Presented at: International Health Economic Association (iHEA) 6th World Congress on Health Economics; 2007; Copenha-gen. Abstract of poster presentation T82.
   Google Scholar
• Pfizer Inc. Selzentry (maraviroc). Prescribing information (US Label). 2007.
   Google Scholar
• Oostenbrink JB, Al MJ. The analysis of incomplete cost data due to dropout. Health Econ. 2005;14(8):763–776.
   PubMed Web of Science ®Google Scholar
• Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York: John Wiley & Sons, Inc; 1987:166–167.
   Google Scholar
• Henry K, Tebas P, Lane C. Explaining, predicting, and treating HIV-associated CD4 cell loss: after 25 years still a puzzle. J Am Med Assoc. 2006;296(12)1 523–1525.
   Web of Science ®Google Scholar
• Arias E. United States Life Tables, 2003. National Vital Statistics Reports, vol. 54 no. 14. Hyattsville, MD: National Center for Health Statistics; 2006.
   Google Scholar
• Albrecht MA, Bosch RJ, Hammer SM, et al. Nelfinavir, efa-virenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med. 2001;345(6):398–407.
   PubMed Web of Science ®Google Scholar
• Baxter JD, Mayers DL, Wentworth DN, et al. A rondom-ized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS. 2000;14(9):F83–F93.
   PubMed Web of Science ®Google Scholar
• Gulick RM, Ribaudo HJ, Shikuma CM, et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. J Am Med Assoc. 2006;296(7):769–781.
   PubMed Web of Science ®Google Scholar
• Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in per-sons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337(11):725–733.
   PubMed Web of Science ®Google Scholar
• Raffi F, Katlama C, Saag M, et al. Week-12 response to therapy as a predictor of week 24,48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials. Clin Infect Dis. 2006;42(6):870–877.
   PubMed Web of Science ®Google Scholar
• Deeks SG, Barbour JD, Grant RM, Martin JN. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS. 2002;16(2):201–207.
   PubMed Web of Science ®Google Scholar
• US Public Health Service and the Infectious Diseases Soci-ety of America. Guidelines for the prevention of opportu-nistic infections among HIV-infected persons - 2002. June 14,2002. Available at: http://www.aidsinfo.nih.govidefault.aspx.
   Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Ado-lescents. Guidelines for the use of antiretroviral agents in HIV-1 -infected adults and adolescents. Washington, DC: US Department of Health and Human Services; 2008:1–128.
   Google Scholar
• Zbrozek AS, Cantor SB, Cardenas MP, Hill DP, Jr. Phar-macoeconomic analysis of ondansetron versus metoclo-pramide for cisplatin-induced nausea and vomiting. Am J Hosp Pharm 1994 June 15;51(12):1555–63.
   PubMedGoogle Scholar
• Paltiel AD, Scharfstein JA, Seage GR III, et al. A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection. Med Decis Making. 1998;18(2 Suppl):S93–105.
   PubMed Web of Science ®Google Scholar
• Schackman BR, Goldie SJ, Freedberg KA, Losina E, Bra-zier J, Weinstein MC. Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decis Mak-ing. 2002;22(1):27–38.
   PubMed Web of Science ®Google Scholar
• Drug Topic. Red Book. Montvale, NJ: 2006.
   Google Scholar
• US Department of Labor Bureau of Labor Statistics. Available at: http:www.b1s.gov/cpi/cpi_dr.htm. Accessed May 2008.
   Google Scholar
• Brazier J, Usherwood T, Harper R, Thomas K. Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol. 1998;51:1115–1128.
   PubMed Web of Science ®Google Scholar
• Ware JE Jr, Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (1Q0LA) Project. J Clin Epidemiol. 1998;51:903–912.
   PubMed Web of Science ®Google Scholar
• Wu AW, Reviski DA, Jacobson DL, Malitz FE. Evidence for reliability, validity and usefulness of the Medical Out-comes Study HIV Health Survey (MOS-HIV). Qual Life Res. 1997;6:481–493.
   PubMed Web of Science ®Google Scholar
• Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
   Google Scholar
• Tsevat J, Sherman SN, McElwee JA, et al. The will to live among HIV-infected patients. Ann Intern Med. 1999;131(3):194–198.
   PubMed Web of Science ®Google Scholar
• Simpson KN, Luo MP, Chumney E, Sun E, Brun S, Ashraf T. Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection. HIV Clin Trials. 2004;5(5):294–304.
   PubMed Web of Science ®Google Scholar
• Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis. 2009;49(9): 1441–1449.
   PubMed Web of Science ®Google Scholar
• Elbasha EE, Szucs T, Chaudhary MA, et al. Cost-effective-ness of raltegravir in antiretroviral treatment-experienced HIV-1-infected patients in Switzerland. HIV Clin Trials. 2009;10(4):233–253.
   PubMed Web of Science ®Google Scholar
• Delobel P, Sandres-Saune K, Cazabat M, et al. R5 to X4 switch of the predominant HIV-1 population in cellular res-ervoirs during effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2005;38(4):382–392.
   PubMed Web of Science ®Google Scholar
• van der Ryst E, Westby M. Changes in HIV-1 co-recep-tor tropism for patients participating in the maraviroc MOTIVATE 1 and 2 clinical trials. In: Program and abstracts of the 47th Annual Interscience Conference on Antimicro-bial Agents and Chemotherapy; September 17–20, 2007; Chicago, IL. Abstract H–715.
   Google Scholar
• Freedberg KA, Scharfstein JA, Seage GR III, et al. The cost-effectiveness of preventing AIDS-related opportunis-tic infections. J Am Med Assoc. 1998;279(2):1 30–136.
   Web of Science ®Google Scholar
• Freedberg KA, Hirschhorn LR, Schackman BR, et al. Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patients. J Acquir Immune Defic Syndr 2006;43(Suppl 1):S113–S118.
   PubMed Web of Science ®Google Scholar
• Goldie SJ, Paltiel AD, Weinstein MC, et al. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med. 2003;115(8):632–641.
   PubMed Web of Science ®Google Scholar
• Kimmel AD, Goldie SJ, Walensky RP, et al. Optimal fre-quency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients. Antivir Ther 2005;10(1):41–52.
   PubMed Web of Science ®Google Scholar
• Sax PE, Islam R, Walensky RP, et al. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis. 2005;41(9):1316–1323.
   PubMed Web of Science ®Google Scholar
• Schackman BR, Goldie SJ, Weinstein MC, Losina E, Zhang H, Freedberg KA. Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults. Am J Public Health. 200191(9):1456–1463.
   Google Scholar
• Asmuth D, Goodrich J, Cooper D, et al. CD4+ cell resto-ration after 48 weeks in the maraviroc (MVC) treatment-experienced (TE) trials MOTIVATE 1 and 2. In: Program and abstracts of the Annual XVII International AIDS Conference; 2008; Mexico. Abstract of poster presentation TUPE0050.
   Google Scholar
• Nelson M, Arasteh K, Clotet B, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experi-enced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005;40(4):404–412.
   PubMed Web of Science ®Google Scholar
• Raffi F. Clinical efficacy and tolerance of enfuvirtide (Fuzeon), new antiretroviral inhibitors of intracellular pen-etration of human immunodeficiency virus (HIV) type 1. Med Mal Infect. 2004;34( Spec No 1):8–17.
   PubMed Web of Science ®Google Scholar